List of Figures
- Figure 2-1: Global - Leukemia Incidences & Deaths, 2020 & 2030
- Figure 2-2: Global - Leukemia Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
- Figure 2-3: Global - Leukemia Antibodies Therapeutics Market Size by Type (US$ Million), 2021
- Figure 2-4: Global - Leukemia Antibodies Therapeutics Market Size by Type (%), 2021
- Figure 2-5: Global - Leukemia Antibodies Therapeutics Market Size by Region (US$ Billion), 2021
- Figure 2-6: Global - Leukemia Antibodies Therapeutics Market Size by Region (%), 2021
- Figure 2-7: Global - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
- Figure 2-8: US - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
- Figure 2-9: Europe - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
- Figure 2-10: China - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
- Figure 2-11: Japan - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
- Figure 3-1: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
- Figure 3-2: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
- Figure 3-3: Global - Leukemia Antibodies in Clinical Trials by Phase, 2022 till 2028
- Figure 3-4: Global - Leukemia Antibodies in Clinical Trials by Patient Segment, 2022 till 2028
- Figure 4-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
- Figure 4-2: Mylotarg - Approval Year by Region
- Figure 4-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), May'2022
- Figure 4-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May'2022
- Figure 4-5: Mylotarg - Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
- Figure 4-6: Mylotarg - Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May'2022
- Figure 4-7: Mylotarg - Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
- Figure 4-8: Mylotarg - Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
- Figure 4-9: Mylotarg - Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
- Figure 4-10: Mylotarg - Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), May'2022
- Figure 4-11: Mylotarg - Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, May'2022
- Figure 4-12: Besponsa - Approval Year by Region
- Figure 4-13: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), May'2022
- Figure 4-14: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May'2022
- Figure 4-15: Besponsa - Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
- Figure 4-16: Besponsa - Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
- Figure 4-17: Besponsa - Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), May'2022
- Figure 4-18: Besponsa - Duration of Treatment of ALL - After & Without HSCT (Weeks)
- Figure 4-19: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
- Figure 4-20: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks)
- Figure 4-21: Lumoxitin - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), May'2022
- Figure 5-1: Rituxan - FDA Approval Year by Indication
- Figure 5-2: MabThera - Approval Year by Region
- Figure 5-3: US- Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for
Injection (US$), May'2022
- Figure 5-4: US - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for
Injection (US$), May'2022
- Figure 5-5: US - Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for
Injection (US$), May'2022
- Figure 5-6: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for
Injection (GBP/US$), May'2022
- Figure 5-7: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for
Injection (GBP/US$), May'2022
- Figure 5-8: Rituxan - Average Cost for Single Dose & Cost of Full Maintenance Phase
for CLL (US$), May'2022
- Figure 5-9: Truxima - Price for a Supply of 10 ml & Price Per ml of Solution for
Injection (US$), May'2022
- Figure 5-10: Truxima - Price for a Supply of 50 ml & Price Per ml of Solution for
Injection (US$), May'2022
- Figure 5-11: UK - Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of
Solution (GBP/US$), May'2022
- Figure 5-12: UK - Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of
Vial (GBP/US$), May'2022
- Figure 5-13: Truxima - Average Cost for Single Dose & Cost of Full Maintenance
Phase for CLL (US$), May'2022
- Figure 5-14: Riabni - Cost of Supply of 10ml & Per Unit Price of 10mg/ml
Intravenous Solution (US$), May'2022
- Figure 5-15: Riabni - Cost of Supply of 50ml & Per Unit Price of 10mg/ml
Intravenous Solution (US$), May'2022
- Figure 5-16: Riabni - Average Cost for Single Dose & Cost of Full Maintenance Phase
for CLL (US$), May'2022
- Figure 5-17: Ruxience - Approval Year by Region
- Figure 5-18: US - Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml
Intravenous Solution (US$), May2022
- Figure 5-19: US - Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml
Intravenous Solution (US$), May2022
- Figure 5-20: UK - Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of
Solution (GBP/US$), May'2022
- Figure 5-21: UK - Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of
Solution (GBP/US$), May'2022
- Figure 5-22: Riabni - Average Cost for Single Dose & Cost of Full Maintenance Phase
for CLL (US$), May'2022
- Figure 5-23: Rituxan Hycela - Price for 11.7 ml Supply & Price Per ml of 23,400
units-1,400mg/11.7 ml Subcutaneous Solution (US$), May'2022
- Figure 5-24: Rituxan Hycela - Price for 13.4 ml Supply & Price Per ml of 26,800
units-1,600 mg/13.4ml Subcutaneous Solution (US$), May'2022
- Figure 5-25: Rituxan Hycela - Duration of CLL Treatment (Weeks)
- Figure 5-26: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of
CLL (US$), May'2022
- Figure 5-27: Gazyva - Approval Year by Cancer Type
- Figure 5-28: Gazyva - Price for 40ml Supply & Price Per ml of Intravenous Solution
(US$), May'2022
- Figure 5-29: Gazyva - Recommended Dosing Schedule for Initial Treatment Cycle of
CLL (mg)
- Figure 5-30: Gazyva - Duration of Single Treatment Cycle & Full Treatment of CLL
(Week)
- Figure 5-31: Gazyva - Cost of Initial & Subsequent Treatment Cycle & Full
Treatment Cost of CLL (US$), February'2022
- Figure 5-32: Arzerra - Price for a Supply of 15 ml, 5 ml and Price per ml of
Intravenous Solution (US$), May'2022
- Figure 5-33: Arzerra - Price for a Supply of 50 ml & Price Per ml of Intravenous
Solution (US$), May'2022
- Figure 5-34: Arzerra - Initial & Maintenance Dose for Previously Untreated CLL (mg)
- Figure 5-35: Arzerra - Minimum & Maximum Treatment Duration for Previously
Untreated CLL (Weeks)
- Figure 5-36: Arzerra - Minimum & Maximum Treatment Cost for Previously
Untreated CLL (US$), May'2022
- Figure 5-37: Arzerra - Initial & Maintenance Dose for Relapsed CLL (mg)
- Figure 5-38: Arzerra - Minimum & Maximum Treatment Cost for Relapsed CLL (US$),
May'2022
- Figure 5-39: Arzerra - Initial & Maintenance Dose for Refractory CLL (mg)
- Figure 5-40: Arzerra - Treatment Duration for Refractory CLL (Weeks)
- Figure 5-41: Arzerra - Minimum & Maximum Treatment Cost for Refractory CLL (US$), May'2022
- Figure 6-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL
- Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)
- Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), May'2022
- Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
- Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
- Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), February'2022
- Figure 7-1: Besponsa - Quarter 1 Sales by Region (US$ Million), 2022
- Figure 7-2: Besponsa - Quarter 1 Sales by Region (%), 2022
- Figure 7-3: Global - Besponsa Annual Sales (US$ Million), 2020 & 2021
- Figure 7-4: Global - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
- Figure 7-5: US - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
- Figure 7-6: Europe - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
- Figure 7-7: ROW - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
- Figure 7-8: Besponsa - Annual Sales by Region (US$ Million), 2020 & 2021
- Figure 7-9: Besponsa - Quarterly Sales by Region (%), 2020
- Figure 7-10: Besponsa - Quarterly Sales by Region (%), 2021
- Figure 7-11: Rituxan - Quarter -1 Value by Region (US$/CHF Million), 2022
- Figure 7-12: Global - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
- Figure 7-13: US - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
- Figure 7-14: Europe - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
- Figure 7-15: Japan - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
- Figure 7-16: ROW - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
- Figure 7-17: Rituxan - Annual Sales Value by Region (US$/CHF Million), 2021
- Figure 7-18: Rituxan - Annual Sales Value by Region (%), 2021
- Figure 7-19: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
- Figure 7-20: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
- Figure 7-21: Gazyva - Quarter -1 Value by Region (US$/CHF Million), 2022
- Figure 7-22: Global - Gazyva Annual Sales Value (US$/CHF Million), 2018 - 2021
- Figure 7-23: US - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
- Figure 7-24: Europe - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
- Figure 7-25: Japan - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
- Figure 7-26: ROW - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
- Figure 7-27: Gazyva - Annual Sales Value by Region (US$/CHF Million), 2021
- Figure 7-28: Gazyva - Annual Sales Value by Region (%), 2021
- Figure 7-29: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
- Figure 7-30: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
- Figure 7-31: Blincyto - Quarter 1 Sales by Region (US$ Million), 2022
- Figure 7-32: Blincyto - Quarter 1 Sales by Region (%), 2022
- Figure 7-33: Blincyto - Sales Value (US$ Million), 2018 - 2021
- Figure 7-34: US - Blincyto Sales Value (US$ Million), 2018 - 2021
- Figure 7-35: ROW - Blincyto Sales Value (US$ Million), 2018 - 2021
- Figure 7-36: Global - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4'2021
- Figure 7-37: US - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4'2021
- Figure 7-38: ROW - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4'2021
- Figure 7-39: Blincyto - Annual Sales Value by Region (US$ Million), 2021
- Figure 7-40: Blincyto - Annual Sales Value by Region (%), 2021